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Abstract There is considerable evidence that purines are
vasoactive molecules involved in the regulation of blood
flow. Adenosine is a well known vasodilator that also acts as
a modulator of the response to other vasoactive substances.
Adenosine exerts its effects by interacting with adenosine
receptors. These are metabotropic G-protein coupled recep-
tors and include four subtypes, A1, A2A, A2B and A3.
Adenosine triphosphate (ATP) is a co-transmitter in
vascular neuroeffector junctions and is known to activate
two distinct types of P2 receptors, P2X (ionotropic) and
P2Y (metabotropic). ATP can exert either vasoconstrictive
or vasorelaxant effects, depending on the P2 receptor
subtype involved. Splanchnic vascular beds are of partic-
ular interest, as they receive a large fraction of the cardiac
output. This review focus on purinergic receptors role in the
splanchnic vasomotor control. Here, we give an overview
on the distribution and diversity of effects of purinergic
receptors in splanchnic vessels. Pre- and post-junctional
receptormediated responses are summarized. Attention is
also given to the interactions between purinergic receptors
and other receptors in the splanchnic circulation.
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Introduction
Almost fifty years separate the first report of extracellular
actions of purine nucleotides and nucleosides by Drury and
Szent-Györgyi in 1929 [39] and the definition of purinergic
receptors by Burnstock in 1976 [18]. In the last few
decades, a lot of research has been made in what concerns
purinergic receptors and it is nowadays established that
extracellular nucleotides and nucleosides are released by
cells to provide the primary components for purinegic
responses [43]. Purinergic receptors are important regula-
tors of the blood flow, since they mediate vasoconstriction,
vasodilation and neurotransmitter release. The splanchnic
circulation is composed of gastric, small intestinal, colonic,
pancreatic, hepatic and splenic circulations, arranged in
parallel with one another. The major arteries supplying
the splanchnic organs are the celiac artery, the superior
mesenteric artery and inferior mesenteric artery, which
branch off from the aorta and give rise to smaller arteries
that anastomose extensively. Splanchnic blood is drained to
the liver via the portal vein, and flows from the liver to the
inferior vena cava via the hepatic veins [101, 127]. Since
the splanchnic circulation receives about 25% of the cardiac
output, alterations in the splanchnic circulation may have
important clinical consequences. This review will foccus
on the distribution and function of purinergic receptors
particularly in vessels of the splanchnic circulation.
According to the IUPHAR Committee on Receptor
Nomenclature and Drug Classification (NC-IUPHAR)
[51], purinergic receptors comprise adenosine receptors
and P2 receptors, given that their endogenous agonist is
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adenosine or adenosine triphosphate (ATP), respectively. P2
receptors are further divided in P2X receptors, which are
ionotropic ligand-gated ion channel receptors, and P2Y
receptors, which are metabotropic G protein-coupled
receptors.
There are four different adenosine receptors, denoted A1,
A2A, A2B, and A3 [52]. All of them have been cloned in
several different animal species, including human. Adeno-
sine receptors are G protein-coupled receptors. Classically,
they have been distinguished by those that couple to Gi
proteins, the adenosine A1 and A3 receptors, and those that
are coupled to Gs proteins, the adenosine A2A and A2B
receptors. Nowadays, adenosine receptors are viewed as
pleiotropic receptors since for the four of them there is
evidence of distinct profiles of coupling to different G
proteins and to different transducing systems, according to
their degree of activation and with their particular localiza-
tion [52].
P2X receptors are a family of seven proteins (P2X1–
P2X7) [77]. All P2X receptors are ligand-gated ion channel-
type, with almost equal permeability to Na+ and K+, and
significant permeability to Ca2+ [46]. The seven P2X
subunits form functional receptors that are named homo-
meric P2X receptors when expressed alone or heteromeric
P2X receptors if they result from the combination of
different subunits. Often native cell types express multiple
P2X subunit mRNA transcripts and multiple P2X subunits.
It is not clear how many subunits are required in each
heteromer, which ones dominate, or if a greater number of
heteromers can be formed [78, 121, 163]. P2X6 subunits
form only heteromeric channels and P2X7 subunits only
homomeric channels [173]. P2X receptors form as multi-
meric assemblies of channel subunits. The exact stoichi-
ometry of the receptor remains unclear although studies
have suggested that the channel may be comprised of at
least three subunits [163].
The family of the P2Y receptors includes, for now, 14
different receptors. The P2Y1, P2Y2, P2Y4, P2Y6, P2Y11,
P2Y12 and P2Y13 receptors are the mammalian receptors,
while the P2Y3, P2Y5, P2Y7, P2Y8, P2Y9 and P2Y10
receptors represent receptors cloned from non-mammalian
vertebrates or receptors that are currently under functional
characterization [1]. Based on (1) sequence homology, (2)
the presence of key amino acids essential for receptor
activation, (3) chromosomal colocalization, (4) similarity of
the cognate ligand, and (5) identification of uridine
diphosphate (UDP)-glucose in the extracellular space, the
IUPHAR Subcommittee recently rename the UDP-glucose
receptor the P2Y14 receptor [1].
P2Y receptors are metabotropic G protein-coupled
receptors and although P2Y receptors couple to specific G
proteins, one given P2Y receptor can couple to functionally
distinct G proteins and signalling pathways [2]. This
provides the opportunity for agonist-specific signaling
involving distinct active conformations of the receptor
which raises the possibility of pursuing selective targets
with therapeutic relevance. However, there are no studies
on this issue in what concerns the splanchnic circulation.
Pharmacologically, P2Y receptors can be subdivided into
the adenine-nucleotide-preferring receptors mainly respond-
ing to adenosine diphosphate (ADP) and ATP (human and
rodent P2Y1, P2Y12 and P2Y13, and human P2Y11), the
uracil-nucleotide-preferring receptors (human P2Y4 and
P2Y6) responding to either uridine triphosphate (UTP) or
UDP, receptors of mixed selectivity (human and rodent
P2Y2 and rodent P2Y4), and receptors responding only to
UDP-glucose and UDP-galactose (P2Y14) [2].
Adenosine receptors in the splanchnic circulation
Despite the existence of several studies describing a role for
adenosine in the regulation of splanchnic circulation [48, 55,
87, 118, 150, 151], there is little information concerning to
adenosine receptors distribution in these vascular beds. Till
now, expression of adenosine receptors in splanchnic vessels
has been evaluated only in the mesenteric vasculature [36,
71]. Western-blot analysis and quantitative densitometry
revealed that mesenteric microvessels from Wistar rats
express all the adenosine receptors subtypes, i.e., A1, A2A,
A2B and A3 receptors. A2A and A3 receptors were found to
be abundantly expressed in these vessels [71]. Similar results
were also found by reverse transcriptase polymerase chain
reaction (RT-PCR) studies in the Sprague Dawley rat
mesenteric vascular bed, thus suggesting an important
physiological role for A2A and A3 receptors in the regulation
of intestinal blood flow [36]. Binding assays with selective
ligands for A2A receptors also evidenced the presence of this
receptor subtype in the rabbit mesenteric artery [31]. There
are, however, some differences concerning to adenosine A1
receptor expression. A1 receptor protein appears to be
significantly expressed in mesenteric microvessels from
Wistar rats [71], while A1 receptor mRNA was undetected
in the mesenteric vascular bed from Sprague Dawley rats
[36]. These contrasting results may be due to technique
limitations or to differences between rat strains. It is also
possible that the authors studied different segments of the
mesenteric vascular bed. While Jackson et al [71] specified
that 2nd and 3rd order branches of the mesenteric vascula-
ture were used, Donoso et al [36] just refers to the
mesenteric arterial bed. Moreover, the inclusion of sympa-
thetic nerve fibers in the homogenate could also account for
the discrepancy in the A1 receptor expression.
Table 1 summarizes the information on the distribution
of adenosine receptors in vessels of the splanchnic
circulation.
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Effects mediated by adenosine receptors
in the splanchnic circulation
Considerable evidence indicates that adenosine acts as a
modulator of sympathetic neurotransmission, exerting either
inhibitory or facilitatory effects. The regulation of noradren-
aline release by adenosine has been observed in several
vascular (tail artery, saphenous vein, portal vein, mesenteric
artery, hepatic artery, pancreatic-duodenal arteries) [14, 33,
68, 69, 176] and non-vascular tissues (kidney, adrenal
medulla, vas deferens, heart) [42, 84, 132, 174, 186].
Adenosine inhibitory effect on noradrenergic transmis-
sion has been generally attributed to the activation of
prejunctional A1 receptors [17, 34, 58, 74, 92, 158]. With
respect to the splanchnic circulation, the majority of studies
also points to a sympathoinhibitory role of adenosine
mediated via A1 receptors. In rabbit mesenteric arteries,
adenosine and its analogs depressed neuroeffector trans-
mission [68]. The rank order of potency of various agonists,
R-N6-(phenylisopropyl-adenosine) (R-PIA)≌ 5′-(N-ethyl-
carboxamido)-adenosine (NECA)> S-N6-(phenylisopropyl-
adenosine) (S-PIA)>adenosine, suggested that these actions
were mediated by A1 receptors [68].
An A1 receptor with a modulatory effect on sympathetic
neurotransmission was also identified in other vessels and
species. In the rabbit portal vein, adenosine also inhibited
the contractile response evoked by adrenergic nerve
stimulation via activation of presynaptic adenosine recep-
tors of the A1 subtype [14]. In the hamster mesenteric
arterial bed, sympathoinhibition was also shown to be
mediated by prejunctional A1 receptors [136]. A similar role
was also observed for this adenosine receptor subtype in the
mesenteric artery from Wistar rat. Adenosine, chloroadeno-
sine (CADO) and NECA inhibited noradrenaline release
while the selective A1 receptor antagonist, 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX) significantly reduced the
inhibition induced by adenosine or its analogs [153].
In contrast with the studies describing the involvement
of prejunctional A1 receptors in sympathoinhibition,
Donoso et al. recently observed that A2A and A3 receptors
reduced the noradrenaline overflow from the nerve termi-
nals of the Sprague Dawley mesenteric arterial bed [36].
The additive inhibitory effects of selective A2A and A3
agonists and the significant increase in noradrenaline
release elicited by the simultaneous blockade of A2A and
A3 receptors, suggest that these receptors are also able to
decrease sympathetic transmission. Furthermore, these
receptors are markedly expressed in the rat mesenteric
vascular bed [36]. In the rat portal vein, it was also
described that the sympathoinhibitory effect of adenosine
and its analogs is mediated by prejunctional adenosine
receptors with characteristics of the A2 subtype [75].
Despite ample evidence describing the adenosine ability
to inhibit noradrenergic transmission, there is a lack of
experimental data supporting a physiological role for
endogenous adenosine as a modulator of sympathetic
neurotransmission. In a rat model of prolonged sympathetic
nerve stimulation associated with decreased tissue perfusion,
the administration of 1,3-dipropyl-8-sulfophenylxanthine
(DPSPX), a non selective antagonist of A1/A2 receptors,
did not affect the mesenteric blood flow nor the noradrenaline
spillover [83]. DPSPX also failed to attenuate noradrenergic
neurotransmission during hemorrhagic hypotension [70].
Similar results were also observed in the hamster mesenteric
arterial bed, where the application of DPCPX had no
effect on contractile responses elicited by electrical field
stimulation [136]. It has been described that activation of
presynaptic α2-adrenoceptors reduces the inhibitory effect
on noradrenaline release of A1-receptor activation [4, 15,
91]. It is possible that, in splanchnic vascular beds, the
adenosine inhibitory effect on transmitter release is
revealed when presynaptic α2-adrenoceptors are blocked,
as previously observed in other tissues [58, 61, 84]. These
results suggest that endogenous adenosine may not reach
a sufficient level to exert a physiological effect within the
neuroeffector junction. However, it remains possible, that
under pathophysiological conditions or in tissues with
higher metabolic demand, endogenous adenosine may
assume a significant role as a modulator of sympathetic
neurotransmission.
Table 1 Distribution of adenosine receptors in vessels of the splanchnic circulation
Adenosine Receptor Preparation Technique Expression Reference
A1 Rat mesenteric microvessels Western Blot and quantitative densitometry Strongly expressed [71]
Rat mesenteric vascular bed RT-PCR Not detected [36]
A2A Rat mesenteric microvessels Western Blot and quantitative densitometry Very strongly expressed [36, 71]
Rat mesenteric vascular bed RT-PCR Strongly expressed [31]
Rabbit mesenteric artery Binding assay
A2B Rat mesenteric microvessels Western Blot and quantitative densitometry Low density [71]
Rat mesenteric vascular bed RT-PCR Weakly expressed [36]
A3 Rat mesenteric microvessels Western Blot and quantitative densitometry Very strongly expressed [71]
Rat mesenteric vascular bed RT-PCR Strongly expressed [36]
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It is a well known fact that sympathetic neurons release
both noradrenaline and ATP, which function as co-transmitters
[156, 157]. Examples of this adrenergic-purinergic cotrans-
mission have also been observed in splanchnic vascular
tissues such as mesenteric artery [181], mesenteric vein [155]
and hepatic artery [12]. Activation of adenosine A1 receptors
by exogenous applied adenosine or its analogues has been
shown to inhibit the release of both adrenergic and purinergic
transmitters [38]. Moreover, the A1-receptor mediated
inhibition of ATP release appears to be more pronounced
than the inhibition of noradrenaline overflow [38]. Regarding
the splanchnic circulation, in rabbit mesenteric arteries, the
activation of presynaptic A1 receptors by adenosine also
seems to inhibit ATP release [68]. Furthermore, in canine
splenic arteries, the continuous infusion of ATP inhibited
both noradrenaline and ATP releases [187]. This inhibitory
effect was attributed to the activation of A1 receptors by
adenosine readily generated from ATP and was partially
reversed by the A1-adenosine receptor antagonist, 8-
phenyltheophylline [187].
In addition to its inhibitory action on adrenergic and
purinergic neurotransmission, A1 receptors also appear to
regulate non adrenergic non cholinergic transmission
(NANC). The release of the NANC transmitter, calcitonin
gene-related peptide, during perivascular nerve stimulation
in rat mesenteric arterial bed was inhibited in the presence
of adenosine receptor agonists and this effect was shown to
be mediated by prejunctional A1 receptors [146]. This inter-
pretation was based in the order of potency obtained for the
adenosine receptor agonists tested, N6-ciclopentyladenosine
(CPA)≥R-PIA≥NECA≥CADO≥S-PIA and in the effects
obtained in the presence of selective A1 or A2 receptors
antagonists (DPCPX and 3-[4-[2-[[6-amino-9[(2R,3R,4S,5S)-
5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]purin2yl]
amino]ethyl] phenyl]propanoic acid (CGS21680), respec-
tively) [146].
Adenosine elicits vasodilatation in several splanchnic
vessels, leading to an increase in blood flow and a decrease
in vascular resistance. The vasorelaxant response to
adenosine or its analogs has been observed in mesenteric,
hepatic, gastric and pancreatic vascular beds [23, 24, 87,
102, 159,194]. The spleen circulation appears to be an
exception, since the splenic arterial conductance was shown
to be reduced in response to the administration of the
adenosine analog, CGS21680 [120]. There is consensus
that the vasodilatory effects of adenosine are mediated by
A2 receptors. However, it is still a matter of debate which
A2 receptor subclass, i.e., A2A or A2B, is involved in these
vasorelaxant responses. In mesenteric vessels both A2A and
A2B receptors seem to contribute to vasodilatation. Indeed,
it was previously observed that these A2 receptor subtypes
are expressed in the mesenteric vascular bed, although A2B
receptors are weakly expressed in comparison to A2A
receptors [71]. A2A receptor-mediated vasodilatory effects
have been observed in the rat and rabbit mesenteric artery
[31, 64, 79, 133]. These effects appear to involve the
opening of potassium channels subsequent to A2A receptor
activation. As previously referred, A2 receptors are coupled
to Gs proteins, which activate adenylyl cyclase leading to
an increase in intracellular cAMP. The elevation of cAMP
further activates protein kinase A, which opens potassium
channels probably through a phosphorylation step [79].
A vasodilatory response to adenosine mediated by A2A
receptors was also observed in the portal vein and in the
pancreatic vascular bed [59, 87].
In contrast, other studies in the rat mesenteric artery
point to an A2B-mediated vasodilatation, based on the
potency order for NECA, adenosine and CGS21680
(NECA>adenosine>CGS21680). In these works, the selec-
tive A2A receptor antagonist failed to induce vasodilatation,
unless high concentrations were used [131, 145]. A2B
receptors seem to be primarily located on the smooth
muscle. However, their contribution to vasodilatation
appears to occur only in conditions of blockade of
adenosine uptake. When the uptake is operational, adeno-
sine and its analogs seem to activate a xanthine-resistant
site which may be intracellular [131].
Adenosine-induced vasodilatation in splanchnic vessels
appears to be dependent, at least in part, on the presence of a
functional endothelium [167]. However, it does not seem to
involve the release of nitric oxide (NO), since the vaso-
dilatory response to adenosine or its analogs was not
reduced by the blockade of NO synthesis in the isolated
mesenteric artery and gastric resistance vessels [25, 64, 145].
Although it is well established that adenosine-induced
vasodilation is mediated by A2 receptors, the administration
of the selective A1 antagonist, DPCPX, was shown to
abolish the glucose-induced increase in pancreatic islet
blood flow. This surprising finding suggests that A1
receptors may also contribute to the vasorelaxant response
in this vascular bed [22].
The magnitude of adenosine vasodilatory effects seems
to vary with the caliber of the vessels. For instance, in the
mesenteric arterial bed the pre-capillary arterioles showed
the largest increases in diameter in response to adenosine,
when compared to the effects in principal arterioles [103].
A similar effect was also observed in the venous side of the
mesenteric circulation [103]. An opposite situation appears
to occur in the hepatic vascular bed, where adenosine was
shown to dilate the hepatic artery and the portal vein, but
not the intrahepatic portal resistance vessels [23, 88].
Table 2 summarizes the information on the potencies of
agonists and antagonists at adenosine receptors in the
splanchnic circulation.
Just recently, the possibility of crosstalk between
prejunctional facilitatory angiotensin II receptors and
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inhibitory adenosine and P2 receptors has emerged. It was
described that in the rat mesenteric vein, but not in the
artery, tonic activation of adenosine A1 receptors, but not
P2X receptors, amplify the facilitatory effect of angiotensin
II on noradrenaline relase induced by electrical field
stimulation [169]. Adenosine-angiotensin II interactions
were also described in the mesenteric vasculature of rats
chronically infused with DPSPX, a non selective antagonist
of A1/A2 adenosine receptors [106]. These rats have been
shown to develop hypertension, marked vascular hypertro-
phy and hyperplasia, activation of the renin-angiotensin
system and altered vascular reactivity [3, 106, 107, 126,
160]. Recently, it was described that the angiotensin II
facilitatory effect on noradrenaline release was increased in
mesenteric artery from DPSPX-treated rats. In contrast, the
acute exposure of mesenteric vessels from control rats to
Table 2 Potencies of agonists and antagonists at adenosine receptors in the splanchnic circulation





































Predominant receptor considered to be involved on the basis of functional data and receptor localization studies. Values ± S.E.M. or 95%
confidence interval (in parenthesis). EC50, EC40 and EC20 represent the molar concentration of the agonist nedded to cause 50%, 40% and 20% of
the maximum response, respectively; pEC50, pEC40 and pEC20 are the negative logarithme to base 10 of the EC50, EC40 and EC20 of an agonist,
respectively; pA2 is the negative logarithme to base 10 of the molar concentration of the antagonist that makes it necessary to double the
concentration of the agonist nedded to elicit the original response. 8-sulphophenyltheophylline (8-SPT); N6-(3-iodo-benzyl)-adenosine-
5′-N-methyluronamide (IB-MECA); 5′-(N-ethylcarboxamido)-adenosine (NECA); chloroadenosine (CADO); N6 -ciclopentyladenosine (CPA);
R-N6 -(phenylisopropyl-adenosine) (R-PIA); S-N6 -(phenylisopropyl-adenosine) (S-PIA); 3-[4-[2-[[6-amino-9[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-
3,4-dihydroxy-oxolan-2-yl]purin2yl]amino]ethyl]phenyl]propanoic acid (CGS21680); [3 H]-4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]
triazin-5-ylamino]ethyl)phenol (ZM241385).
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DPSPX in vitro did not affect the facilitatory action of
angiotensin II [106]. Also, in rat perfused mesentery intra-
arterial infusions of DPSPX did not alter the effects of intra-
arterial or intravenous angiotensin II on periarterial nerve
stimulation or on vascular tone [66]. It is possible, however,
that acute versus chronic blockade of adenosine receptors
has different consequences and that the putative crosstalk is
only evident after prolonged exposure to DPSPX. Further
studies are needed to better characterize these interactions.
Portal hypertension results in both increased portal
pressure and reduced splanchnic vascular resistance, lead-
ing to marked splanchnic hyperemia [141]. The pronounced
arterial vasodilation and increased systemic and mesenteric
artery blood flow observed in portal hypertension leads to
systemic hypotension, despite an increased blood volume
and cardiac output. The adenosine-mediated mesenteric
vasodilation depends on a functional endothelium [32, 64,
167]. Adenosine vasodilation is commonly described to
involve A2A receptor activation, although A2B receptors
may also play a role [6, 49, 124]. There is evidence of both
A2A [64] or A2B receptor-mediated vasodilation [131, 145]
in the mesenteric artery. Experimental differences (species,
methodology) may explain the discordant information
regarding to the adenosine receptor responsible for the
relaxant response in mesenteric arteries of the rat [31]. An
A2A receptor-mediated relaxation of mesenteric arteries can
be observed in the rat, as described in the rabbit [31, 64].
The importance of this adenosine-induced vasodilation is
further stressed by the fact that chronic blockade of
adenosine receptors leads to hypertension [3].
The vascular responses to vasoactive agents are modified
in portal hypertension [28, 53, 89]. The rabbit model of
partial portal vein ligation to study portal hypertension is
characterized by the development of portal-systemic shunt-
ing [5, 26]. In rabbits with portal hypertension the
vasodilation of the cranial mesenteric artery induced by
adenosine is decreased both in vitro [30] and in vivo [100].
In portal hypertensive animals, there was mainly a
decreased potency but also a decreased eficacy of all tested
adenosine agonists compared to normal animals. Concom-
itantly, there was a decreased adenosine plasma level and a
decreased binding density of [3H]-CGS21680 and [3H]-4-
(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-
5-ylamino]ethyl)phenol (ZM241385) to mesenteric artery
membranes from portal hypertensive compared to normal
rabbits [31]. The adenosine receptor responsible for the
adenosine-induced relaxation of mesenteric arteries is of the
A2A subtype and the reduced density of these A2A receptors
may contribute for the reduced relaxant response to
adenosine in the mesenteric arteries of portal hypertensive
animals. Thus, de Brito et al. [31] hypothesized that
hypertension-induced changes in the uptake and/or metab-
olism of plasma adenosine may have contributed for the
significant decrease in adenosine plasma levels observed in
their study. The most likely explanation for the observed
decrease in the potency and eficacy of adenosine receptor
agonists to induce mesenteric relaxation in portal hyperten-
sive rabbits resides on the observed decreased density of
adenosine A2A receptors.
P2X and P2Y receptors in the splanchnic circulation
In 1993, Bo and Burnstock [7] provided direct evidence for
the existence of P2X receptors in the vascular smooth
muscle using a radioligand binding assay and autoradiog-
raphy with [3H]α,β-methylene ATP ([3H]α,β-meATP).
Already in this study, the authors reported regional and
species differences in the distribution of P2X receptors [7]:
(1) medium- and small-sized arteries had higher densities
than the elastic and large muscular arteries, and (2) in some
large muscular arteries, such as the rabbit hepatic and
mesenteric arteries, the outer region of the vessel had a
higher density of receptors than the inner region. In the
guinea-pig and rat portal veins, the longitudinal muscle has
much higher densities of P2X receptors than does the
circular muscle, while in the rabbit portal vein the circular
muscle has higher density of P2X receptors than the
longitudinal muscle [7]. In the rabbit mesenteric vein, very
low quantities of [3H]α,β-meATP were observed [7].
[3H]α,β-meATP is almost ineffective as an agonist at some
P2X receptors [165] and has a complex binding profile
[104], which limits the interest of ligand-binding autoradi-
ography using this ligand. Nevertheless, the results of Bo
and Burnstock were further stressed and completed using
different techniques, for the most part in the mesenteric
vasculature. The presence of P2X1-immunoreactivity was
observed in the rat mesenteric artery [54, 60, 62, 90], but
also in arterioles of the submucous plexus of the guinea-pig
ileum [184] and in rat and mouse pancreatic vascular
smooth muscle [29]. Conflicting results have been obtained
in what concerns the venous part of the circulation. Hansen
and co-workers [60] observed P2X1-immunoreactivity in
both the rat mesenteric artery and vein while Galligan and
co-workers [54] described the presence of P2X1-immuno-
reactivity in rat mesenteric arteries, but not in mesenteric
veins. Using RT-PCR, mRNA of P2X1 receptors has been
detected in rat hepatic [130] and mesenteric [129] arteries.
However, there is a report of no detection of mRNA
transcripts of P2X1 receptors in the mesenteric artery of the
rat [122]. Differences in the mesenteric arteries analysed
can account for the conflicting results, since the former
study used the superior mesenteric artery [122] while the
latter study studied segments of superior and 2nd-order
mesenteric arteries [129]. However, immunohistochemical
analysis [57] revealed no major differences in the pattern of
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P2X receptor isoform expression between the three sizes of
vessel and may suggest that a novel additional subunit is
expressed in large arteries.
Another pertinent question is where in the vascular wall
are P2X1 receptors located? In this way, the majority if not
almost all, of the studies in which this issue was persecuted,
have found P2X1 receptors in the smooth muscle cell of the
media [7, 29, 60, 90, 184]. Very recently, a study of
Harrington and Mitchell [62] reported for the first time the
presence of P2X1-immunoreactivity in all the three layers
of the rat mesenteric artery: not only in the smooth muscle
cells of the media, but also in the adventia and in the
endothelium. Curiously, the small P2X1-receptor cluster
identified by Hansen and co-workers was restricted to the
adventitial surface of the media and to endothelial cells
[60]. Opposedly to these studies, Lewis and Evans failed to
detect P2X1-immunoreactivity on the endothelium [90]. It
seems that P2X1 receptors are not located on nerves since
they are still identified after destruction of the sympathetic
nerves with 6-hydroxydopamine [60].
Some controversy exists concerning the distribution of
P2X2 receptors in the splanchnic circulation. RT-PCR
studies showed that P2X2 receptors are either absent [122]
or weakly expressed in rat mesenteric artery and rat hepatic
artery [130]. In contrast, immunohistochemistry studies
identify the presence of P2X2 receptors in the nerves and
endothelial cells of the rat mesenteric artery and vein [60],
in nerve fibers of the perivascular plexuses of the guinea-
pig ileum [184] and also in the smooth muscle of the rat
mesenteric artery and vein [60] and pancreatic vascular bed
[29]. Interestingly, two splice variants of the P2X2 receptors
have been identified in rat coronary artery and aorta [122].
Regarding the other P2X receptors, the P2X3 receptor is
weakly expressed both in the rat hepatic [130] and
mesenteric [129] arteries. In contrast, the P2X4 and the
P2X7 receptors are reported to be very strongly expressed in
the rat hepatic [130] and mesenteric [129] arteries, although
some authors described no detection of P2X4 mRNA
transcripts [122]. The P2X5 receptor is strongly expressed
in the rat hepatic artery [130] but weakly expressed in rat
mesenteric artery [129]. Till now, the P2X6 receptor was
never detected in the splanchnic vasculature [129, 130].
In summary, with the exception of the P2X6 receptor, all
the other P2X receptors are expressed in the splanchnic
circulation, at least in arteries. P2X1, P2X4, P2X5 and P2X7
receptors are strongly expressed while P2X2 and P2X3
receptors are weakly expressed. This difference may be
associated with the particular role that each P2X receptor
plays in the splanchnic circulation. However, functional
studies only evidence the major role of P2X1 receptor in
mediating arterial vasoconstriction (see below). Even the
late slow and sustained relaxation observed in response to
ATP has been suggested to be mediated by P2X1 receptors
(see below). Further studies are required to conclude about
this issue since although it is now possible to block gene
expression and raise mice with deletion of P2 receptors, the
study of the P2X receptors is still held back by the lack of
potent and selective antagonists.
Not so much information exists concerning the distribu-
tion of P2Y receptors in splanchnic vessels. In general, P2Y
receptors are found both on vascular endothelial and
smooth muscle cells [40, 138]. RT-PCR studies found
mRNA fragments for P2Y1, P2Y2 and P2Y6 receptors in
the rat [21] and mouse [177] mesenteric arteries, while
P2Y4 mRNA wasn’t detected [21]. Moreover, P2Y1- and
P2Y2-immunoreactivity was present in the smooth muscle
of the rat pancreatic vascular bed [29]. Functional studies
identify the presence of P2Y1 receptors in the rat mesenteric
vein [54] and P2Y2 receptors in the guinea pig mesenteric
vein [116].
Table 3 summarizes the information on the distribution
of P2-purinoceptors in vessels of the splanchnic circulation.
Effects mediated by P2X and P2Y receptors
in the splanchnic circulation
The previous notion that noradrenaline was the single
sympathetic neurotransmitter in vascular neuroeffector
junctions has given place to the actual fact that ATP is a
co-transmitter at this synapses [180]. In what concerns the
splanchnic circulation, the first description of such co-
release was reported by Su [164] in the rabbit portal vein.
Since then, growing evidence emerged that ATP is a co-
transmitter in the splanchnic circulation of the dog [9, 94,
113, 114, 144, 170], rabbit [140, 181], guinea-pig [8], and
rat [19, 37, 44].
The co-release of noradrenaline and ATP from sympa-
thetic nerve terminals may be subject to separate modula-
tory mechanisms. Differential autoinhibition has been
suggested in the rat mesenteric artery [41]. In the rabbit
ileocolic artery, activation of presynaptic α2-adrenoceptors
preferentially inhibits the release of noradrenaline [16]. In
canine splenic arteries, adrenergic neuron blockade with
guanethidine [189] or inhibition of sodium channels by
tetrodotoxin [188] mainly depresses the adrenergic rather
than the purinergic component. Opposing to this, the
purinergic component is depressed, rather than the adren-
ergic component, after irreversible degeneration of adren-
ergic nerve fibres due to cold storage [190] or with
dipyridamole [119]. Electrochemical and electrophysiolog-
ical studies have also tried to clarify whether noradrenaline
and ATP are co-stored and/or co-released. In vascular
tissues not belonging to the splanchnic circulation, it seems
that noradrenaline and ATP are released in parallel [110,
111], although these results are still controversal [109]. This
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hypothesis of different storage has also been put into
discussion in the rat mesenteric artery [41]. Differences in
the methods used to quantify noradrenaline and ATP may
account for the ambiguos results since the electrochemically
measured noradrenaline may originate from both “small”
and “large” dense cored vesicles, whereas excitatory junc-
tion potentials are believed to result only from ATP released
from “small” dense cored vesicles [162].
It is generally accepted that periarterial nerve stimulation
at low frequencies mostly causes a release of purinergic
transmitter whereas stimulation at high frequencies mainly
induces a release of adrenergic transmitter [142–144, 187,
192]. Modulation of ATP release by noradrenaline can only
be revealed during nerve stimulation of very low frequen-
cies (0.2±2 Hz) and short duration (10 s) [9, 117]. Parallel
with what has been described on transmitter release, the
neurogenic contractions induced by electrical field stimula-
tion of postganglionic sympathetic nerves within splanchnic
vessels are biphasic [16, 94, 144, 154]. In dog [115] and
rabbit mesenteric arteries [181], the first component is
purinergic in nature, develops rapidly, is transient and
predominates at low frequencies (1–2 Hz) of stimulation,
whereas the second component is adrenergic, develops after
the purinergic one, is more long-lasting and becomes more
evident as the frequency of stimulation increases (10 Hz).
Based on these findings, it was speculated that the
purinergic component is involved more dominantly in the
early phase of the total response, while the adrenergic
component mainly contributes to the latter phase [115]. The
fact that exogenous ATP produces a rapid and transient
contraction and mimicked the neurogenic purinergic re-
sponse suggested that the profile of neurogenic purinergic
transmission reflects postjunctional rather than prejunc-
tional mechanisms [115]. However, it has also been
suggested that ATP released from the endothelium may
function as a modulator of sympathetic neurotransmission
and contribute to the purinergic constriction component,
since the removal of the endothelium decreased the
Table 3 Distribution of P2-purinoceptors in vessels of the splanchnic circulation.
P2 Receptor Preparation Technique Expression Reference






Rat hepatic artery RT-PCR Yes [130]
Rat mesenteric vein Immunohistochemistry Yes [54, 60]
Guinea-pig arterioles of the ileum submucous plexus Immunohistochemistry Yes [184]
Rat and mouse pancreatic vascular bed Immunohistochemistry Yes [29]
P2X2 Rat mesenteric artery and vein Immunohistochemistry Low density [60]
Strongly stained [29]
Rat and mouse pancreatic vascular bed None [122]
Rat mesenteric artery RT-PCR Weak [129]
Rat hepatic artery Weak [130]
P2X3 Rat hepatic artery RT-PCR Weakly expressed [130]
Rat mesenteric artery Weakly expressed [129]
P2X4 Rat hepatic artery RT-PCR Strongly expressed [130]
Rat mesenteric artery Very strongly expressed [129]
Not expressed [122]
P2X5 Rat hepatic artery RT-PCR Strongly expressed [130]
Rat mesenteric artery Weakly expressed [129]
P2X6 Rat hepatic and mesenteric arteries RT-PCR Never detected [129, 130]
P2X7 Rat hepatic artery RT-PCR Strongly expressed [130]
Rat mesenteric artery Strongly expressed [129]
P2Y12 Rat mesenteric artery RT-PCR Yes [21]
Mouse mesenteric artery RT-PCR Yes [177]
Rat and mouse pancreatic vascular bed Immunohistochemistry Yes [29]
Rat mesenteric vein Functional study Yes [54]
Guinea pig mesenteric vein Yes [116]
P2Y4 Rat mesenteric artery RT-PCR None [21]
P2Y6 Rat mesenteric artery RT-PCR Yes [21]
Mouse mesenteric artery RT-PCR Yes [177]
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purinergic component but not the adrenergic component of
the vasoconstrictor responses to stimulation [191]. Func-
tionally, neurogenic released ATP evokes biphasic
responses on the vascular smooth muscle: initially direct
excitatory junction potentials followed by indirect hyper-
polarization through the release of endothelium-derived
hyperpolarizing factor (EDHF) [172]. Interestingly, there is
a report of ATP being partially responsible for the
neurogenic NANC endothelium-independent relaxation of
the longitudinal muscle of the rabbit portal vein [13]. This
ATP-mediated neurogenic relaxation seems to come about
via P2 receptors located on the smooth muscle [13, 76]. A
study suggested that the sympathetic purinergic contractile
responses of the dog mesenteric artery may be caused by an
unknown substance selective to P2X-purinergic receptors,
rather than ATP [114]. Alternatively, neurogenically re-
leased ATP may act only on the P2X-purinergic receptors,
unlike exogenously ATP [114].
An important point concerning differential proportions
of the purinergic and adrenergic components of the sym-
pathetic neurotransmission refers to the calibre of the
vessels in question. This issue is effectively evaluated in
the mesenteric vasculature where it is possible to study
vessels with quite different internal diameters. It is generally
agreed that the importance of the purinergic component
increases and that of the adrenergic component decreases
with the reduction of the size of the mesenteric arteries [56,
93]. If one thinks that in small mesenteric arteries the
neurogenic purinergic component of the periarterial nerve
stimulation dominates [56, 93], that small mesenteric
arteries are more sensible to α,β-meATP and UTP than large
arteries [57], and even more, that in small (but not large)
mesenteric arteries both P2X1 and P2Y2 receptors are found
(see references below), it makes sense that neurally released
ATP in this small vessels induces an immediately direct
vasoconstriction, through activation of P2X1 receptors and a
later indirect endothelium-dependent vasorelaxation via
activation of P2Y2 receptors and the release of EDHF [172].
Sympathetic cotransmission also seems be dependent on
the species and/or regional tissue studied. As previously
pointed out, the majority of the studies show that low
frequencies of stimulation favour purinergic neurotransmis-
sion while high frequencies promote adrenergic neurotrans-
mission [142, 143, 187, 192]. A variation was found in the
canine gastroepiploic [170] and splenic artery [192]. In
these preparations, the first phase is mediated by P2X
receptors at low frequencies of stimulation, but also
presynaptic α-adrenoceptors at high frequencies, while the
second phase response involves mostly α1-adrenoceptors
and partially P2X receptor activations at all frequencies
used. Uniquely, electrical stimulation (100 pulses, 10 Hz) of
the guinea-pig submucosal arterioles caused vasoconstic-
tion mediated by activation of P2X receptors by ATP or a
related purine nucleotide [47]. The functional role of
neurally released noradrenaline in this tissue appears to be
restricted to its prejunctional modulation of transmitter
release [47].
The electrical and contractile response elicited with
stimulation of sympathetic nerves has been shown to differ
significantly between arteries and veins. For instance, in the
guinea-pig mesenteric artery, sympathetic nerve stimulation
gives rise to rapidly rising excitatory junction potentials of
brief duration that are resistant to prazosin, but are blocked
by α,β-meATP [67, 82]. In contrast, in the guinea-pig
mesenteric vein a slow depolarization [166] that is resistant
to purinoceptor desensitization with α,β-meATP [65, 67] is
observed rather than fast EJPs. This has led to the
conclusion that ATP is not involved in these junctional
events [65, 67] and, hence, is not released during nerve
stimulation. However, a study on guinea-pig mesenteric
vessels [155] revealed that arterial contractile response to
sympathetic nerve stimulation is due exclusively to nor-
adrenaline, whereas at least three different neurotransmit-
ters (noradrenaline, ATP and neuropeptide Y) appear to
contribute to the venous neural response. In another study,
electric field stimulation induced ATP overflow in the
guinea-pig mesenteric vein [8]. The difference in the
contribution of ATP to the neural response in artery and
vein was suggested to be related to the presence of different
populations of ATP receptors, i.e., in artery, rapidly
desensitizing P2X1 receptors predominate whereas in vein,
non-desensitizing P2Y receptors predominate [116]. How-
ever, the apparent contradictory results between these
different studies [67, 82, 155] may also be ascribed to
differences in the methodological approaches (evaluation of
membrane potentials by electrophysiology vs contractile
and [3H]-noradrenaline release studies) or to the size of the
vessels studied (the studies of Kreulen [82] involved a
broader range of internal diameters of the vessels). Besides,
there might be differences in the postjunctional effects of
prejunctionally released neurotransmitters, as it is suggested
to occur in the human saphenous vein [147], where ATP is
co-released with noradrenaline but did not appear to
generate the non-adrenergic component of contraction. In
the guinea-pig, release of both ATP and noradrenaline in
mesenteric veins exceeds release in arteries [8]. Differently,
in the dog, release of noradrenaline in veins exceeds release
of noradrenaline in arteries, whereas both vessels release
equal amount of ATP [9].
Whether ATP by itself or indirectly after degradation to
adenosine modulates sympathetic neurotransmission is
another point of interest in the context of this review.
Inhibition of sympathetic neurotransmission via prejunc-
tional P2 receptors has been described in a number of
tissues from rat and mouse [182] although little investiga-
tion has pursuit this issue in the splanchnic vasculature. In
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the dog mesenteric artery αβ-meATP had no effect on [3H]
noradrenaline release, suggesting that the P2 purinoceptor
is absent or not functioning in the sympathetic nerve
terminals [115]. In the rat mesenteric artery, ATP inhibition
of noradrenaline release occurs without the conversion of
ATP to adenosine [153]. However, the inhibition was com-
pletely abolished by DPCPX, an antagonist of adenosine
A1 receptors, and pyridoxal-phosphate-6-azophenyl-2′,4′-
disulphonic acid (PPADS), an antagonist of P2 receptors,
suggesting that that the receptor involved may be different
from the well known adenosine A1 or P2-receptors [153].
On the contrary, in the hamster mesenteric arterial bed,
prejunctional adenosine A1, but not P2, receptors modulate
sympathetic neurotransmission [136]. The purinergic com-
ponent of sympathetic neurotransmission does not con-
tribute significantly to sympathetic contractile responses of
this vascular bed [136, 139]. It was suggested that inhibitory
P2 receptors are expressed selectively on sympathetic nerves
utilizing ATP as a cotransmitter, in accordance with the view
that prejunctional P2 receptors on sympathetic nerve ter-
minals are release-modulating autoreceptors [178, 183].
Another possibility is that endothelium-derived factors
released upon activation of endothelial UTP-sensitive P2Y
receptors inhibit ATP release from purinergic nerves in the
smooth muscle cells of hamster mesenteric artery [171].
ATP elicits arterial contraction through stimulation of
P2X receptors in the mesenteric artery of the rat [54, 73, 85,
123, 137], guinea-pig [116] and rabbit [20], and in the rat
hepatic artery [130] and the guinea-pig portal vein [125].
The P2X1 subtype is the receptor responsible for the purine
nucleotides-induced arterial contractions [54, 177]. In
contrast to what is observed in the arteries, venoconstriction
is mainly mediated by P2Y2 receptors [54, 116, 123],
although P2Y1 receptors (and possibly P2Y4 and P2Y6
receptors) and to smaller extent P2X1 receptors [116] may
also play a role. In the perfused rat mesenteric artery, a
residual contractile response to ATP was observed after
exposure to P2X antagonists [123]. Also, in isolated 2nd-
order rat mesenteric arteries UTP-induced contractions
persisted after desensitization of P2X1 receptors [54]. These
studies suggest that other P2 receptor(s), probably P2Y2
receptors, contribute to the arterial contractile effect of
purine nucleotides although playing a minor role [54, 123].
A P2Y receptor-mediated contractile effect has been
described previously although not in the splanchnic circula-
tion [63, 149, 179]. More recently, a study in mesenteric
arteries from P2X1-KO mice revealed that although P2X1
receptors underlie an important component of the sympa-
thetic neurogenic contraction, UTP and ADP, but not ATP,
evoked concentration-dependent arterial contraction [177],
suggesting the presence of a UTP- and UDP-sensitive P2Y
receptor. These authors propose the P2Y6 receptor as a
candidate for mediating this sustained vasoconstriction
[177]. However, a very recent work of the same group
[86] concluded that P2X1 receptors are required to generate
the junctional calcium transients that activate this compo-
nent of the neurogenic contraction, since they were not
observed in P2X1-KO mice. This observation doesn’t
exclude the possibility raised in previous studies of P2X1
receptors being the principal mediators of purinergic
contraction with other receptors playing minimal roles. In
line with the view that both P2X and P2Y receptors partici-
pate in vasocontraction is the study of Lagaud and co-
workers [85]. These authors described that both P2X- and
P2Y-receptor mediated arterial contractions through dif-
ferent mechanisms. P2X receptors are activated by low
concentrations of ATP (μM range) and induce depolariza-
tion of the cell leading to the opening of voltage-dependent
Ca2+ channels and direct calcium influx. Additionally, P2Y-
purinoceptors are activated by high concentrations of ATP
(mM range) which promote first a calcium influx through
activation of a PTX-sensitive G protein and a dihydropyridine-
sensitive mechanism, and secondly a release of calcium from
intracellular stores via the phospholipase C/IP3 pathway. In
contrast, a study in the guinea-pig small mesenteric arteries
couldn’t observe P2X-mediated effects [108]. The dissimilar
results obtained concerning the exclusivity of P2X1 recep-
tors or the result of both P2X/P2Y receptors in mediating
purinergic contraction probably reflect differences between
species, as previously suggested [177].
The seven P2X subunits can form functional homomeric
or heteromeric P2X receptors (see Introduction). The
finding of mRNA for some P2X receptors with no evidence
for a functional role [130] and the pharmacology evidence
for some yet ununidentified P2X receptors [57, 175] has
been suggesting that arteries may express heteromeric P2X
receptors with properties dominated by the P2X1 receptor
subunit. The blood pressure of P2X1 receptor-deficient
mice was normal or slightly elevated [112], suggesting that
P2X1 receptors may not be essential for the expression of
arterial P2X receptors, although P2X receptors are not the
only receptors that regulate blood pressure levels. On the
contrary, in P2X1-KO mice ATP-mediated vasoconstric-
tions were abolished [177], suggesting that P2X1 receptor
subunit is essential for the production of functional P2X
receptors. However, one has to consider the possibility that
there is compensation of other P2X receptors in these
animals.
Activation of endothelial P2Y receptors causes arterial
dilation [137]. This vasodilation is probably mediated by
P2Y1 and P2Y2 receptors, through hyperpolarization of the
endothelium that correlates with endothelium-dependent
vasodilation [105]. This P2Y receptor-induced endothelium-
mediated vasodilation occurs through the release of NO, via
the NO/cGMP pathway [21], and cyclo-oxigenase metabo-
lites [97, 105] but also via the release of EDHF [97, 98, 99,
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105, 148]. In fact, EDHF-mediated vasodilation seems to be
the predominant mediator of P2 receptor-mediated regulation
of perfusion pressure in the small arteries of the peripheral
circulation [96, 172]. Both NO- and EDHF-mediated vaso-
dilation can be induced by activation of P2Y1, P2Y2 and
P2Y4, but not P2Y6, receptors [95–98].
Some important features are associated with the endothelial
P2Y-induced EDHF-mediated vasodilation. First, it is not
observed in all vessels. Malmsjo an co-workers [97] reported
that it occurs in the rat mesenteric artery but not in the
carotid artery. Second, it depends on the resting tone of the
vessel. In rat mesenteric arteries it was only observed in
arteries which were under a low resting tone (1 mN) [97].
Finally it may vary dramatically according to the vessel’s
internal diameter. P2Y2 receptor-induced EDHF-mediated
relaxation was clearly evident in large diameter main branch
of the rat mesenteric artery (internal diameter of about
1.24 mm) but almost absent in the rat small mesenteric
arteries (internal diameter of about 340 μm) [105]. In another
study [172], electrical stimulation or adventitial application
of ATP induced endothelium-dependent hyperpolarization in
thin hamster mesenteric arteries (internal diameter < 150 μm)
but not in thick arteries (internal diameter > 300 μm).
Usually, the importance of EDHF versus nitric oxide
generally increases as the vessel diameter is reduced [152].
The results of Thapaliya and co-workers are more coherent
with this view. However, as the stimulus was electrical
stimulation or adventitial application of ATP, the higher
number of smooth muscle cell layers was probably determi-
nant for the absence of hyperpolarization in thick mesenteric
arteries. This hypothesis is reinforced by the fact that intimal
application of ATP could induce endothelium hyperpolariza-
tion [172]. In what concerns the study of Mistry and co-
workers, differences in the distribution and/or transduction
signalling of the endothelial P2Y2 receptors, a counteracting
effect of constrictor P2Y2 receptors in the smooth muscle
cell or other P2 receptors, namely P2X receptors, could
mask the vasodilatory effect in small mesenteric arteries.
Indeed, activation of P2X receptors counteracts the hyper-
polarization of vascular smooth muscle cells mediated by
P2Y-induced release of EDHF [98, 99] but not NO [96].
Furthermore, species differences may also account for the
different profile of the two studies. Curiously, in arteries of
about 350 μm, neither electrical stimulation or adventitial
administration of ATP induced hyperpolarization [172] nor
stimulation os P2Y2 receptors with ATPγS caused vasodila-
tion [105].
At a glance, it seems that the effects of ATP on the
vasculature are quite clear-cut. P2X receptors, namely P2X1
present on vascular smooth muscle cells, are responsible for
the ATP-induced vasoconstriction, while P2Y receptors,
mainly P2Y2 located on vascular endothelial cells, mediate
ATP-induced vasodilation. However, the effects of ATP on
vessels are much more multifaceted. Recent reports of ATP
inducing endothelium-independent relaxations [59, 135]
and the evidence for the presence of P2X1 receptors on
vascular endothelial cells [62] increased the complexity of
the effects of ATP on splanchnic circulation. ATP can
induce three types of response in mesenteric arterial bed of
the rat [62, 72, 135, 161]: (1) contraction, mainly mediated
by smooth muscle P2X1 receptors, (2) rapid and transient
relaxation, mainly mediated by P2Y2 receptors, and (3)
slow and sustained relaxation. The mechanism responsible
for this prolonged relaxation is controversial and has only
very recently started to be characterized [62, 134, 135].
Guibert and co-workers [59] described an endothelium-
independent ATP-induced relaxation that was attributed to
the conversion of ATP to adenosine by ectonucleotidases
[59]. The first study that tried to characterize the receptor
mediating this sustained possibly endothelium-independent
relaxation induced by ATP was signed by Ralevic [135].
This study couldn’t conclude on the purinergic receptor
involved. In a second study, Ralevic [134] concluded that
smooth muscle P2X receptors were responsible for a biphasic
response: contraction and prolonged relaxation, although a
role of P2Y receptors could not be excluded, since the
sustained relaxation was not abolished by P2X receptor
dessensitization [135]. Concurrently with the studies of
Ralevic, prolonged relaxation to ATP has been reported to
be abolished by removal of the endothelium [161]. In a even
more recent study [62], it was clearly shown that α,β-mATP
induced endothelium-dependent vasodilation which was also
independent from the contractile effect. The preparation and
methods used to remove the endothelium can explain, at
least in part, the opposite results. While Ralevic used the
isolated perfused mesenteric vascular bed, a preparation in
which it is difficult to remove the endothelium, and endo-
thelium removal with distilled water, Stanford and co-
workers used sodium deoxycholate to endothelium-denude
the arteries. In the study of Harrington and Mitchell,
however, isolated rings of 2nd-order rat mesenteric arteries
(mean internal diameter of 247 μm) were mounted on a wire
myograph and the endothelium was physically removed by a
human hair and a permanent control of the process was
performed to ensure that it didn’t lesion the smooth muscle
cells. Moreover, it should be noticed that the study of
Guibert was the only in which a vein (the rat portal vein)
was used. As happens with other situations, there can be
differences in the distribution and function of purinergic
receptors between the arterial and the venous side of the
circulation. The study of Harrington and Mitchell further
evidenced, for the first time, the presence of P2X1-like
immunoreactivity in the surface of the endothelium, and
concluded that the ATP-induced endothelium-dependent
dilation was mainly mediated by P2X1 receptors through
the release of EDHF. In this context, it is interesting to
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Table 4 Potencies of agonists and antagonists at P2X and P2Y receptors in the splanchnic circulation
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notice that renal arteries, which express P2X1 receptors
on the smooth muscle cells but not on endothelial cells,
contract without subsequent vasodilation in response to
α,β-mATP [80].
Table 4 summarizes the information on the potencies of
agonists and antagonists at P2X and P2Y receptors in the
splanchnic circulation.
Mistry and co-workers suggested the existence of
interactions between P2Y receptors subtypes. They observed
that in rat mesenteric artery, relaxation of smooth muscle
cells and hyperpolarization of endothelial cells caused by
the P2Y2 receptor agonist ATPγS were potentiated in the
presence of MRS 2179, an antagonist of P2Y1 receptors
[105], as previously reported in non-splanchnic vessels [27,
35, 128].
Future perspectives
This review summarized the data on the distribution and
function of purinergic receptors particularly in vessels of the
splanchnic circulation. The splanchnic circulation receives
Table 4 (continued)






















α,β-meATP 2.7 6.1±0.2 [95]
6.76±0.09 [177]








Predominant receptor considered to be involved on the basis of functional data and receptor localization studies. Values ± S.E.M. or 95%
confidence interval (in parenthesis). Slope referes to the slope of the concentration-response curve; EC50 represents the molar concentration of the
agonist nedded to cause 50% of the maximum response; pEC50 and pEC25 are the negative logarithme to base 10 of the EC50 and EC25 of an
agonist, respectively; pEC25′ is the negative logarithme to base 10 of the concentration of the agonist nedded to cause an increase of 25 mmHg in
blood pressure; pA2 is the negative logarithme to base 10 of the molar concentration of the antagonist that makes it necessary to double the
concentration of the agonist nedded to elicit the original response.
β,γ-methylene ATP (β,γ-meATP); 2-methylthio ATP (2MeSATP); adenosine 5′-O-3-thiotriphosphate (ATPγS); N6-methyl-2′-deoxyadenosine-
3′,5′-bisphosphate (MRS2179); adenosine 5′-O-thiodiphosphate (ADPβS); adenosine 5′-O-3-thiotriphosphate (ATPγS); 2-methylthioADP (2-
MeSADP); uridine 5′-O-3-thiotriphosphate (UTPγS); uridine 5′-O-thiodiphosphate (UDPβS); a,β-methylene ATP (a,β-meATP); adenosine
triphosphate (ATP); adenosine diphosphate (ADP); uridine triphosphate (UTP); uridine disphosphate (UDP).
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about one fourth of the cardiac output. Blood flow through
the superior mesenteric artery significantly increases in a
post-prandial situation [168]. In humans, the gastrointestinal
tract retains its high blood flow priority, even in conditions
of dynamic muscular exercise or in a pressor situation [45,
185]. Thus, the dysregulation of splanchnic vascular tone is
likely to contribute not only to splanchnic organs dysfunc-
tion, but also to the development of marked hemodynamic
effects (e.g. altered mean arterial pressure, heart rate and
total peripheral resistance) and organ failure. In intensive
care patients, inadequate splanchnic perfusion is associated
with increased morbidity and mortality [81].
Purinergic receptors actively participate in the regulation
of splanchnic blood flow and may play an important role in
clinically relevant pathological states. For instance, adenosine
A1 receptor activation seems to contribute to the improve-
ment of splanchnic perfusion in adjunctive direct peritoneal
resuscitation [193]. Purinergic receptors play an important
role in the regulation of vascular and immune cell-mediated
responses. These receptors trigger and mediate acute pro-
cesses that affect cellular metabolism, adhesion, activation or
migration. Repetitive stimulation of purinergic receptors also
causes long-term reactions, like cell proliferation, differen-
tiation and apoptosis, as seen in several chronic inflamma-
tory states. In the cardiovascular system, purines can
influence blood pressure, platelet activation, thrombosis,
inflammatory processes, cardiac function and vasomotor
responses [10, 11, 40, 50]. The study of purinergic receptors
in the splanchnic circulation is a growing field of interest.
More research is needded in order to, in a near future,
originate new drugs specificaly designed to treate patholo-
gies like portal hypertension, isquemic bowel syndrome and
several inflammatory states.
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